trial

A Double-Blind Placebo Controlled Trial of Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of Negative Symptoms in Schizophrenia

NCTId NCT00168311
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Completed
Enrollment 22 (actual)
Sponsored by The Alfred
Primary completion 2007-07
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Completed
Enrollment
22 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2002-08
Primary completion
2007-07
Eligibility
ALL · 18 Years · 70 Years

Interventions & indications

Drugs
Transcranial Magnetic Stimulation

Sponsors

The AlfredLead Sponsor

Investigators

1
Paul B Fitzgerald, MBBS, PhDPrincipal Investigator

Sites

1 total
Melbourne, Australia

Facts & assertions

4 sourced
Enrollment
22
Phase
NA
Primary Completion Date
2007-07
Status
COMPLETED
relationships
The graph out of here
drug
Transcranial Magnetic Stimulation
drug
lead_sponsor
The Alfred
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Paul B Fitzgerald, MBBS, PhD
person